{"organizations": [], "uuid": "61c9d332337ce5d2683bf350c94ab22eba79e795", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-solodyn/valeant-unit-impax-lose-solodyn-antitrust-class-action-appeal-idUSL2N1Q403X", "country": "US", "domain_rank": 408, "title": "Valeant unit, Impax lose Solodyn antitrust class action appeal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.007, "site_type": "news", "published": "2018-02-14T09:15:00.000+02:00", "replies_count": 0, "uuid": "61c9d332337ce5d2683bf350c94ab22eba79e795"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/health-solodyn/valeant-unit-impax-lose-solodyn-antitrust-class-action-appeal-idUSL2N1Q403X", "ord_in_thread": 0, "title": "Valeant unit, Impax lose Solodyn antitrust class action appeal", "locations": [], "entities": {"persons": [{"name": "medicis", "sentiment": "none"}, {"name": "solodyn", "sentiment": "none"}], "locations": [{"name": "solodyn", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}], "organizations": [{"name": "federal appeals court", "sentiment": "neutral"}, {"name": "impax", "sentiment": "neutral"}, {"name": "westlaw", "sentiment": "none"}, {"name": "impax laboratories inc", "sentiment": "none"}, {"name": "valeant pharmaceuticals international inc", "sentiment": "none"}, {"name": "medicis pharmaceutical corp", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "1st u.s. circuit court of appeals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A federal appeals court has declined to review an order certifying a class action by purchasers of the acne medication Solodyn alleging Medicis Pharmaceutical Corp sought to delay the launch of generic versions of the drug in violation of antitrust laws.\nThe 1st U.S. Circuit Court of Appeals in Boston on Monday declined to take up the appeal by Medicis, a unit of Valeant Pharmaceuticals International Inc, and generic drugmaker Impax Laboratories Inc, before the case goes to trial on March 12.\nTo read the full story on Westlaw Practitioner Insights, click here: bit.ly/2F0v7FK\n ", "external_links": ["http://bit.ly/2F0v7FK", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T09:15:00.000+02:00", "crawled": "2018-02-14T12:50:45.015+02:00", "highlightTitle": ""}